Compare HSCS & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSCS | BMRA |
|---|---|---|
| Founded | 2007 | 1971 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Medical Specialities | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 6.8M |
| IPO Year | N/A | 1995 |
| Metric | HSCS | BMRA |
|---|---|---|
| Price | $1.99 | $2.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 20.9K | 13.2K |
| Earning Date | 03-16-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.80 | $1.87 |
| 52 Week High | $6.47 | $4.60 |
| Indicator | HSCS | BMRA |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 52.53 |
| Support Level | $1.95 | $2.11 |
| Resistance Level | $2.19 | $2.23 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 47.47 | 66.82 |
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.